Display Settings:

Format

Send to:

Choose Destination
    Radiology. 2011 Oct;261(1):1-2.

    Science to practice: can theranostic fullerenes be used to treat brain tumors?

    Source

    Department of Radiology The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. jwmbulte@mri.jhu.edu

    Abstract

    In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd₃N@C₈₀) labeled with lutetium 177 (¹⁷⁷Lu) and tetraazacyclododecane tetraacetic acid (DOTA) (¹⁷⁷Lu-DOTA-f-Gd₃N@C₈₀) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging.

    © RSNA, 2011.

    PMID:
    21931135
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk